Rodney Ho

Professor, Department of Pharmaceutics, Bioengineering (Adjunct) and Director of the Targeted Long-Acting Combination Antiretroviral Therapy (TLC- ART) Program; Affiliate Member of Clinical Pharmacology, Fred Hutchinson Cancer Research Center; Affiliate Faculty, UW Center for AIDS Research and a member of the Institute of Translational Health Services

Department of Pharmaceutics, Pharmaceutics Faculty

Expertise: Biotechnology, Chronic Disease Pharmacotherapy, Computational Modeling, Cytochrome P450, Drug Interactions, Drug Metabolism, Distribution and Transport, Herbal Medicines, HIV and AIDS, Infectious Diseases, Mass Spectrometry, Oncology, Pharmacogenomics and Personalized Medicine, Pharmacokinetics/Pharmacodynamics, Vaccines and Virology

Telephone: (206) 543-9434

Email: rodneyho@uw.edu

Website: TLC-ART Program Website

Education

  • PhD, University of Tennessee
  • Bachelor of Science, University of California
  • Post-Doctoral Fellow, Stanford University Internal Medicine

Research Interests

Dr. Ho is known for biotechnology and nanotechnology research and education that enable transformation of basic biomedical discovery into therapeutics. His research focuses on biology and treatments of cancer and viral infectious diseases. Some topics include (1) Systems approach to drug and protein transport, delivery, and drug targeting to improve efficacy and safety; (2) Drug-interaction and genetic basis of inter-individual variations in AIDS and cancer therapies; (3) Drug and lipid or biomaterial interaction studies that enable engineering and development of drug delivery systems that enhance drug potency and safety.

Biography

Dr. Ho is a professor and presidential entrepreneurial fellow of the University of Washington, and holds appointments at the Fred Hutchinson Cancer Research Center. He is also an expert on pharmacology and systems approach to drug targeting and antiviral therapy. His research aims to improve the therapeutic efficacy and safety of viral and cancer drugs, medical diagnostic agents and vaccines. He is an elected fellow of the American Association for the Advancement of Science (AAAS) and the American Association of Pharmaceutical Scientists (AAPS). He studies the relationships between drug target distribution and its relationship to disease development in cancer, AIDS, and neurological disorders. Building on this understanding, he has developed a systems Approach to Drug Delivery and Targeting. He is known for his expertise in bio-therapeutics, lipid-drug and -protein interactions, liposomes, lipid nanoparticles, pharmacokinetics, and the interplay between tissue targets and drug penetration. His research has led to enhanced HIV, cancer, and pain medication potency and safety. In addition, he is an editor of the Journal of Pharmaceutical Sciences, and author of “Biotechnology and Biopharmaceuticals: Transforming Proteins and Gene into Drugs.” He has received top honors including the Paul Dawson Biotechnology life-time achievement award, and the AAPS Biotechnology Research achievement, one of AAPS’s highest recognitions.

Selected Publications

PubMed link

Ho, R.J.Y., and Gibaldi, M. “Biotechnology and Biopharmaceuticals: Transforming proteins and genes into drugs,” John Wiley and Sons, N.Y., June 2003; 2nd edition published in 2013.

Crouthamel MH, Kelly, E and Ho RJY. Development of Transgenic Mouse Models for Conditional Gene Knockout in the Blood-Brain and Blood-CSF Barriers, Transgenic Res.21 (1):113-30. 2012.

Ho, RJY and Chien JY. Trends in translational medicine and drug targeting and delivery: New insights on an old concept-Targeted drug delivery with antibody-drug conjugates for cancers. J Pharm Sci 103: 71-7Mar;36(3):481-4. 2014.

Kraft, JC, Freeling, JP, Wang, Z and Ho, RJY. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 103: 29-52. 2014.

Freeling, JP, Koehn, J, Shu, J, Sun, J and Ho, RJY. Long-Acting Three-Drug Combination Anti-HIV Nanoparticles Enhance Drug Exposure in Primate Plasma and Cells within Lymph Nodes and Blood. AIDS 28: 2625-2631, 2015 (highlighted by an accompanying editorial commentary in AIDS)

Zhang YJ, Ho, RJY, Sasaki, T. pH-responsive Artemisinin Dimer in Lipid Nanoparticles: First insight into in vivo Applications of Artemisinin Dimer nanoparticles on Human Breast Cancer. J Pharmaceutical Sciences, doi: 10.1002/jps.24407, 2015